title: [Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV].
abstract: OBJECTIVE
  To investigate the clinical significance of vascular endothelial growth factor (VEGF) levels in serums of colorectal cancer patients at stage IV.
  
  
  METHODS
  Using enzyme linked immunosorbent assay (ELISA) to detect the VEGF levels in serums of 45 colorectal cancer patients at stage IV, and 20 healthy served as normal control.
  
  
  RESULTS
  The mean concentration of VEGF in 45 colorectal cancer patients at the 7 day after operation were significantly lower than that before operation (P<0.01). The mean concentration of VEGF in the patients who benefit from bevacizumab showed no statistical difference from the levels of who did not benefit (P=0.554).
  
  
  CONCLUSIONS
  The VEGF levels in colorectal patients at stage IV are lowed as the load of tumor decrease. The circulating levels of VEGF seem not predict the response to bevacizumab in colorectal cancer patients at stage IV.
authors.affiliation: Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. lala343@126.com
authors.forename: Na
authors.initials: N
authors.lastname: Huang
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Meng-ran
authors.initials: MR
authors.lastname: Cao
authors.forename: Ning
authors.initials: N
authors.lastname: Su
authors.forename: Jin-zhang
authors.initials: JZ
authors.lastname: Chen
authors.forename: Cheng-wei
authors.initials: CW
authors.lastname: Lü
authors.forename: Wang-jun
authors.initials: WJ
authors.lastname: Liao
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Luo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab